The t(4;14)(p16.3;q32), associated with 10-20% of cases of multiple myeloma (MM), deregulates the expression of MMSET and FGFR3. To assess the potential of FGFR3 as a drug target, we evaluated the effects of selective inhibitors on MM and control cell lines. SU5402 and PD173074 specifically inhibited the growth of the two t(4;14)-positive MM lines, KMS-11 and OPM-2. Importantly, inhibition was still observed in the presence of IL-6, a growth factor known to play an important role in MM. Both compounds induced a dose-dependent reduction in cell viability and an increase in apoptosis, accompanied by a decrease in extracellular signal-related kinase phosphorylation. In contrast, no inhibition was seen with either compound against t(4;14)-negative cell lines or NCI-H929, a t(4;14)-positive, FGFR3-negative MM cell line. FGFR3 is thus a plausible candidate for targeted therapy in a subset of MM patients.
Introduction
The t(4;14)(p16. 3;q32) is associated with 10-20% of cases of multiple myeloma (MM) and is believed to dysregulate the expression of two genes, MMSET on the der(4) and FGFR3 on the der (14) . 1 At present, it is not known whether deregulation of either or both of these genes is the critical pathogenetic consequence of the t(4;14), but a role for FGFR3 is suggested by several lines of evidence. FGFR3 is a member of a family of highly related transmembrane receptor tyrosine kinases, which are involved in the regulation of cell growth and proliferation. Overexpression of FGFRs has been described in human prostatic, 2 thyroid, 3 breast 4 and pancreatic 5 carcinoma. In the 8p11 myeloproliferative syndrome (EMS), the tyrosine kinase domain of FGFR1 is constitutively activated by fusion to several different partner genes as a result of various chromosomal translocations. 6 Similarly FGFR3 is activated by fusion to ETV6 in peripheral T-cell lymphoma with the t(4;12)(p16;p13). 7 A number of FGFR point mutations have been identified which also result in constitutive activation of the receptor. These were initially identified in a group of inherited skeletal malformation syndromes including achondroplasia and thanatophoric dysplasia but identical acquired mutations of FGFR3 have been reported in 35% of cases of bladder carcinoma and 25% of cervical carcinoma. 8 These mutations are also found in the majority of t(4;14)-positive MM cell lines and in a minority of t(4;14)-positive primary tumour samples. [9] [10] [11] Functional analysis supports an oncogenic role for FGFR3. The expression of activated FGFR3 in IL-6-dependent murine myeloma cells resulted in IL-6 independence and decreased apoptosis. 12 Mice transplanted with activated FGFR3 developed a rapidly lethal B-cell neoplasm, whereas mice transplanted with the wild-type receptor developed B-cell neoplasms after 1 year, 13 suggesting that FGFR3 overexpression predisposes to malignancy but additional events are required for the development of overt disease. Overall then FGFR3 is an obvious therapeutic target in t(4;14)-positive MM and the aim of this study was to investigate the potential utility of tyrosine kinase inhibitors for the treatment of this disease. Here, we show that the two small molecule FGFR inhibitors SU5402 and PD173074 specifically inhibit t(4;14)-positive FGFR3-positive MM cells.
Materials and methods

Cell lines
Three t(4;14)-positive MM cell lines were studied: KMS-11 was kindly provided by T Otsuki, Kawasaki Medical School, Japan, OPM-2 was obtained from DSMZ GmbH, Braunschweig, Germany and NCI-H929 was obtained from Professor Junia Melo, Imperial College, London. The presence of the t(4;14) was confirmed by fluorescence in situ hybridization using standard procedures. Control cell lines were all t(4;14)-negative: U266 (MM), Ramos and Daudi (Burkitt lymphoma), BaF3/ZNF198-FGFR1 (Ba/F3 transformed by ZNF198-FGFR1 to IL-3 independence), 14 BaF3/BCR-ABL (Ba/F3 cell line transformed by BCR-ABL to IL-3 independence; kindly provided by JV Melo, London). Cells were maintained in tissue culture medium consisting of RPMI 1640 supplemented with 10% foetal calf serum (Gibco BRL) plus 1% penicillin/streptomycin (Gibco BRL) and grown in a humidified incubator maintained at 371C and 5% CO 2 throughout.
Reagents
Four small molecule receptor tyrosine kinase inhibitors were employed in this study, each of which function in a similar manner by competing with ATP for the specific binding site within the catalytic domain of the receptor. SU6668, 
-yl]-urea, selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors 17 and was obtained from Pfizer Global Research and Development (Ann Arbor, MI). The compounds were dissolved in DMSO and stored at À201C. Imatinib mesylate (STI-571), an inhibitor of ABL, PDGFR and KIT but not FGFR tyrosine kinases was provided by Novartis (Basel, Switzerland). Imatinib was dissolved in water and stored at À201C.
Cell proliferation assays
Actively cycling cells were plated in triplicate in 96-well plates at a density of 5 Â 10 3 -10 5 cells per well with 100 ml medium containing 1-50 mM SU5402 or 1-50 nM PD173074 or the equivalent concentration of DMSO as a control. In some assays, IL-6 was added to a concentration of 0.1 ng/ml. Plates were analyzed for cell proliferation daily for 4 days. The analysis was performed using the chromogenic dye [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt; MTS) (Promega, Madison, WI, USA). Absorbance was read after 1 h at 490 nm on an enzyme-linked immunosorbent assay plate reader (Dynatech Laboratories, Billingshurst, UK). Cell growth was calculated as the mean relative increase in optical density from the starting (day zero) value.
Cell viability and apoptosis
Cells were cultured in duplicate with or without inhibitors, stained with 0.4% trypan blue and live cells, defined as those cells which completely excluded blue dye, were counted using a haemocytometer. To identify cells undergoing apoptosis, 5 Â 10 4 cells were cytospun onto slides, stained using the ApoAlert DNA Fragmentation Assay (Clontech, CA, USA) and counterstained using 4 0 ,6 0 -diaminido-2-phenylindole dihydrochloride (DAPI). The proportion of apoptotic cells, defined as those cells that produced a clear green signal on fluorescence microscopy, was assessed by counting a minimum of 200 cells for each slide. Images were obtained using an Olympus Vanox microscope and captured with Smart Capture software (Cambridge Biosciences, UK).
Western blotting
Extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation was analysed using standard SDS-PAGE, electroblotting and enhanced chemiluminescence detection (Amersham Pharmacia Biotech UK Ltd). PhosphoERK 1/2 and ERK 1/2 antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA.
Results and discussion
Anti-FGFR activity of SU5402 and PD173074
Initially we assessed the activity of compounds against Ba/F3 cells that had been transformed to IL-3 independence by ZNF198-FGFR1, a constitutively active tyrosine kinase fusion protein formed as a consequence of the t(8;13) in EMS. 18 Using the MTS cell proliferation assay, both SU5402 and PD173074 inhibited the growth of BaF3/ZNF198-FGFR1 cells in a dosedependent fashion (Figure 1a,c) . The IC 50 for SU5402 was similar to that previously reported at approximately 5 mM, as estimated from the day 4 readings. 18 In contrast, the IC 50 for PD173074 was 5 nm indicating that this compound is 1000 times more active. SU6668 gave inconsistent results and was not clearly inhibitory even at concentrations of 50 mM (data not shown) and was therefore not pursued further. PD173074 did not inhibit Ba/F3 cells that had been transformed by BCR-ABL at concentrations of up to 50 nM, whereas SU5402 caused partial growth inhibition at concentrations X50 mM (Figures 1b,d) . These results confirmed that SU5402 and PD173074 are active specifically against the catalytic activity of FGFR1 and not against tyrosine kinases in general. As expected, imatinib mesylate (1 mM) fully inhibited the growth of BaF3/BCR-ABL but not BaF3/ZNF198-FGFR1 cells (data not shown). In addition to their effect on cell proliferation, both SU5402 and PD173074 induced a dose-dependent decrease in cell viability as assessed by trypan blue staining (Figure 2a,c) and also an increase in the number of apoptotic cells as assessed by the TUNEL assay (Figure 2b,d) . 
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Inhibition of t(4;14)-positive MM cell lines
Given that FGFRs are highly related, we anticipated that compounds with anti-FGFR1 activity would also be active against FGFR3 and hence potentially able to inhibit t(4;14)-positive MM cells. SU5402 and PD173074 were tested initially against the t(4;14)-positive MM cell lines KMS-11 and OPM-2, both of which express FGFR3 and harbour activating mutations of this gene. 9 Using the MTS assay, both compounds induced a dose-dependent reduction in cell proliferation. For SU5402, the IC 50 for both lines was comparable to that seen against the control BaF3/ZNF198-FGFR1 cells. For PD173074, the IC 50 for KMS-11 was comparable to control cells but for OPM-2 it was approximately five times higher (Figure 3a-d) . Importantly, inhibition with SU5402 (Figure 3e ,f) and PD173074 (data not shown) was still observed in the presence of 0.1 ng/ml IL-6, the cytokine that is thought to be the most important growth factor in MM. No inhibition was seen with imatinib mesylate (not shown).
FGFRs signal in part through the Ras/MAP kinase pathway and therefore we assessed the effect of the inhibitors on ERK phosphorylation. As shown in Figure 4 , a dose-dependent reduction in ERK phosphorylation was seen for both lines with SU5402 and PD173074. To determine if SU5402 and PD173074 induced cell death in these lines, we assessed viability and numbers of apoptotic cells. A dose-dependent reduction in cell viability and increase in the proportion of apoptotic cells was seen with SU5402 for both KMS-11 ( Figure 5 ) and OPM-2 (not shown) and with PD173074 for KMS-11.
Although OPM-2 cells treated with PD173074 failed to proliferate, we did not observe a reduction in viability or increase in apoptotic cells. This is consistent with the relatively high IC 50 described above and may, for example, relate to differences in the uptake or metabolism of PD173074 by OPM-2 or the acquisition of additional oncogenic events by this line.
No inhibition of t(4;14)-negative control lines
To determine if the inhibitory effects of SU5402 and PD173074 were specific to t(4;14)-positive cells, these compounds were tested against the MM cell line U266 and the Burkitt lymphoma lines Ramos and Daudi, none of which harbours the t(4;14). For all three lines, there was no reduction in proliferation with up to Dose-dependent decrease in ERK phosphorylation in KMS-11 and OPM-2 by SU5402 or PD173074.
Figure 5
Dose-dependent decrease in cell viability (a, c) and increase in apoptosis (b, d) on treatment of KMS-11 cells by SU5402 or PD173074.
Targeting FGFR3 in multiple myeloma EK Grand et al 50 nM PD173074. U266 was analysed in more detail and showed no reduction in viability, increase in apoptosis or reduction in ERK phosphorylation with up to 100 nM PD173074 ( Figure 6 ). Some growth inhibition of all three lines was seen with SU5402 at concentrations X50 mM. However, even with concentrations up to 100 mM SU5402 there was no inhibition of ERK phosphorylation (not shown), suggesting that any inhibitory effect was unlikely to be mediated by FGFR inhibition. These data indicate that the effects of SU5402 and PD173074 on KMS-11 and OPM-2 are selective.
No inhibition of the t(4;14)-positive, FGFR3-negative MM cell line NCI H929
We were initially surprised to find that there was no inhibition of growth of the t(4;14)-positive MM line NCI H929 by either SU5402 or PD173074. However, this line has been reported to express FGFR3 only very weakly, 19 and to harbour a Ras rather than a FGFR3 mutation. 9 This is consistent with recent data suggesting that up to 30% of IgH-MMSET-positive MM patients are FGFR3-expression negative 20, 21 and explains the absence of an inhibitory effect by SU5402 or PD173074.
Concluding remarks
We have shown a selective inhibitory effect of two tyrosine kinase inhibitors with known anti-FGFR activity, SU5402 and PD173074, against control Ba/F3 cells expressing the constitutively active ZNF198-FGFR1 fusion protein, and also against KMS-11 and OPM-2, t(4;14)-positive MM cell lines that express activated FGFR3. These results suggest that KMS-11 and OPM-2 depend on signalling by activated FGFR3 for their growth and survival. Inhibition of the MM lines was observed even in the presence of IL-6, thought to be the most important growth factor for MM cells. Three t(4;14)-negative lines, as well as a t(4;14)-positive MM line, which does not express FGFR3, were not inhibited. Although activating mutations of FGFR3 are uncommon in primary MM plasma cells, mouse models have demonstrated that FGFR3 overexpression predisposes to lymphoid malignancy and it is likely therefore that overexpression of this gene contributes to the pathogenesis of MM. Our data suggest that FGFR inhibitors may be useful agents in the management of t(4;14)-positive MM patients.
